Disclaimer: The following video is a paid advertisement and viewers are not to consider the contents as an endorsement of products or services by the ANA. The materials, information or opinions provided during the videos are solely those of the individuals and companies involved and do not necessarily represent those of the ANA.
ANA Spotlights: Exploring the Utility of Whole-Genome Sequencing for the Diagnosis and Management of White Matter Disorders
Sponsored By: Illumina
Date/Time: Aired live on Monday, October 18, 2021 - 7:45 PM – 8:45 PM
This session will provide an overview of the current state of WGS and transcriptomics for neurological disorders and discuss the impact results can have on clinical management and long-term outcomes. The presenters will review interim data from an observational study that implemented WGS as a first-tier test in patients with leukodystrophy and provide an overview of the next phase of that study which will evaluate clinical utility up to six months after results.
- Kayla J. Muirhead, MS, LCGC; Children’s Hospital of Philadelphia
- Holly Snyder, MS, LCGC; Illumina, Inc.
- Ryan Taft, PhD; Illumina, Inc.